Results 161 to 170 of about 2,731,118 (178)
Some of the next articles are maybe not open access.

Establishing the role of tigecycline in an era of antimicrobial resistance

Expert Review of Anti-infective Therapy, 2008
Tigecycline is a glycylcycline antibacterial agent derived from minocycline with a broad spectrum of activity. Like tetracycline agents, it inhibits bacterial protein synthesis but is able to bind to target sites with higher affinity and overcome tetracycline-resistance mechanisms due to structural modifications.
Jason J, Schafer, Debra A, Goff
openaire   +2 more sources

Tigecycline therapy in pediatric patients with multidrug resistant bacteremia

Enfermedades Infecciosas y Microbiología Clínica, 2020
Multidrug resistance among bacteria increases the need for new therapeutic options. Tigecycline is one candidate drug, due to property of a wider anti-bacterial spectrum to multi-drug resistant (MDR) pathogens. However, it has still not been approved for use in pediatric patients.In this study the effectiveness and safety of tigecycline in children was
Gulhan, Belgin   +8 more
openaire   +3 more sources

Tigecycline in the Era of Antibiotic Resistance: A Current Review

Current Medicinal Chemistry
Abstract: Tigecycline (TIG) is a broad-spectrum antibiotic of the tetracycline class that evades the resistance mechanisms common to first- and second-generation tetracyclines and is effective against Gram-negative and Gram-positive bacteria, as well as intracellular bacteria.
Jessica L. Ortega-Balleza   +5 more
openaire   +2 more sources

Rapid Development of Acinetobacter baumannii Resistance to Tigecycline

Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy, 2007
A 53‐year‐old woman experienced a multidrug‐resistant (MDR) Acinetobacter baumannii urinary tract infection 5 months after undergoing kidney and liver transplantation. The tigecycline minimum inhibitory concentration (MIC) for her A. baumannii isolate was 1.5 μg/ml; the patient received 2 weeks of therapy with intravenous tigecycline as a 100‐mg ...
Gail E, Reid   +4 more
openaire   +2 more sources

Tigecycline: The answer to beta-lactam and fluoroquinolone resistance?

Journal of Infection, 2006
Patients with serious bacterial infections such as intra-abdominal infections and complicated skin and soft tissue infections are often treated empirically because a delay in appropriate initial antimicrobial therapy has been shown to significantly increase morbidity and mortality.
openaire   +2 more sources

[Resistance of Acinetobacter baumannii to Tigecycline].

Sichuan da xue xue bao. Yi xue ban = Journal of Sichuan University. Medical science edition, 2019
To determine the impact of long-term use of antibiotics and ultraviolet radiation on the resistance of Acinetobacter baumannii to tigecycline and the viability of tigecycline-resistant Acinetobacter baumannii .Three strains of tigecycline sensitive Acinetobacter baumannii were selected. Tigecycline resistance was induced through multi-step method or by
Jun-Yan, Qu, Xiao-Ju, Ü
openaire   +1 more source

Oritavancin and Tigecycline: Investigational Antimicrobials for Multidrug‐Resistant Bacteria

Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy, 2004
The advent of multidrug‐resistant gram‐positive aerobes such as Staphylococcus aureus, Streptococcus pneumoniae , and the enterococci, which are resistant to β‐lactams, vancomycin, and a host of other commonly used antimicrobials, has complicated our approach to antibiotic therapy.
openaire   +2 more sources

A Nosocomial Cluster of Tigecycline- and Vancomycin-Resistant Enterococcus faecium Isolates and the Impact of rpsJ and tet(M) Mutations on Tigecycline Resistance.

Microbial drug resistance (Larchmont, N.Y.), 2021
Tigecycline-resistant enterococci are only rarely detected worldwide. In 2017, the National Reference Centre for Staphylococci and Enterococci noticed a nosocomial cluster of tigecycline- and vancomycin-resistant Enterococcus faecium (TVRE) in a hospital of tertiary care in Northern Germany. Nineteen E.
Jennifer K, Bender   +3 more
openaire   +1 more source

Antibiotic Resistance in the Patient With Cancer: Escalating Challenges and Paths Forward

Ca-A Cancer Journal for Clinicians, 2021
Amila K Nanayakkara   +2 more
exaly  

Home - About - Disclaimer - Privacy